Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01872728
Other study ID # 2012.774
Secondary ID 2012-005831-97
Status Active, not recruiting
Phase Phase 3
First received June 5, 2013
Last updated March 17, 2014
Start date June 2013
Est. completion date December 2014

Study information

Verified date March 2014
Source Hospices Civils de Lyon
Contact n/a
Is FDA regulated No
Health authority France: Agence Nationale de Sécurité du Médicament et des produits de santé
Study type Interventional

Clinical Trial Summary

A bilateral facial block (infraorbital and infratrochlear) will be performed immediately after intubation in patients undergoing outpatient rhinoplasty with 2.5% levobupivacaine (intervention group) or saline as control. Intravenous saline or morphine will be administered at the end of surgery in intervention or control groups, respectively. In case of pain in post-anesthesia care unit (numerical pain score >3 on a 0-10 scale), both groups will receive intravenous morphine titration. The total perioperative morphine consumption (intraoperative and in post-anesthesia care unit) will be compared between groups. Pain intensity, presence of nausea/vomiting and patient's satisfaction will be compared between groups.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 40
Est. completion date December 2014
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Outpatient rhinoplasty

- American Society of Anesthesiologists (ASA) classification I-II

- Affiliated to Social Security

- Written informed consent

Exclusion Criteria:

- Allergy to levobupivacaine

- Incapacity to give consent

- Chronic pain

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Bilateral facial block after general anesthesia before surgery
Bilateral facial block (infraorbital and infratrochlear) after general anesthesia before surgery with intravenous placebo or bilateral block with placebo and intravenous morphine

Locations

Country Name City State
France Hôpital Edouard Herriot Lyon

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total morphine consumption during the perioperative period (operating theater and post-anesthesia care unit) At the end of post-anesthesia care unit stay J0 No
Secondary Pain intensity in post-anesthesia care unit 0-10 numerical rating scale (NRS) : from 0 = no pain to 10 = worst pain imaginable J0 (At arrival in post-operative care unit) No
Secondary Postoperative nausea and vomiting Presence or absence of nausea/vomiting J1 (At day 1 after surgery) No
Secondary Patient satisfaction at day 1 0-3 scale (0 = bad, 1 = poor, 2 = good, 3 = excellent) J1 (At day 1 after surgery) No